Modulation of the cytokine responses in equine macrophages following TACE-inhibition.

The research article discusses the impact of a TNF-alpha converting enzyme (TACE) inhibitor on the release of certain cytokines in different cell models, including human and equine cells, under stimulation with LPS. The study suggests that, similar to human cells, equine TNF-alpha is released from its membrane-bound position by TACE.

Study Objective

In this research, the scientists aimed to explore the effects of inhibiting the TNF-alpha converting enzyme (TACE) on the release of certain cytokines, specifically TNF-alpha, IL-1alpha and IL-6. This was done in the context of three different cell models—U937 cells (a model for human macrophages), an equine macrophage cell line known as eCAS, and primary equine peripheral blood mononuclear cells (PBMCs).

Background and Methodology

• The pro-inflammatory cytokine TNF-alpha plays a key role in many human diseases as well as in equine acute abdominal disorders. Its release mechanism, particularly involving the enzyme TACE, has been studied extensively.
• The researchers carried out experiments to observe the effect of a TACE inhibitor on the release of TNF-alpha, IL-1alpha and IL-6 after stimulating these cells with lipopolysaccharide (LPS).
• LPS, an endotoxin found in the outer membrane of Gram-negative bacteria, is known to stimulate immune responses, including the release of cytokines.

Results and Significance

• The results showed that applying a TACE-inhibitor significantly reduced the release of TNF-alpha, IL-1alpha and IL-6 in both equine cell models. Notably, similar results were obtained in U937 cells, the human cell model.
• This suggests that the mechanisms for TNF-alpha release through TACE are comparable between human and equine cells.
• The findings add to our understanding of inflammatory mechanisms in equine health, and they may also pave the way for potential therapeutic interventions targeting TACE in human or veterinary medicine.